Oragenics Inc (OGEN)

$0.78 -0.06 (-7.23%)
Market Cap 3.59M
Revenue (ttm) 0.00
Net Income (ttm) -10.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 118,500
Avg Vol 418,124
Day's Range N/A - N/A
Shares Out 4.27M
Stochastic %K 14%
Beta 0.90
Analysts Strong Buy
Price Target $2.00

Company Profile

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplif...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 286 7900
Fax: 813 286 7900
Address:
1990 Main Street, Suite 750, Sarasota, United States
RocketQueen
RocketQueen Feb. 4 at 12:57 AM
$OGEN headed for non compliance again
0 · Reply
NMax
NMax Feb. 3 at 8:28 PM
$OGEN Janet Huffman and the Oragenics board appear to be coordinating with Sabby for a pump and dump soon
0 · Reply
RocketQueen
RocketQueen Feb. 3 at 7:14 PM
$OGEN Duck Flats Pharma? Looks like more turd polishing.
0 · Reply
NMax
NMax Feb. 3 at 4:53 PM
$OGEN Investigate Janet (and probably Tony Huffman) and the Oragenics board for defrauding investors with fake project developments/timelines, what appears to be collusion with sabby to manipulate share price and especially the board for allowing such rampant fraud and negligence. Janet and Anthony's other businesses (below) should be investigated for connections to Oragenics as well as any trades related to SOGEN: 4KIDZ Consulting LLC Barrel Brands LLC Florida Office of the Attorney General, Dept. of Legal Affairs: (850) 414-3990 Fbl submit a tip: tips.fbi.gov/violation-sele... SEC submit a tip. sec.gov/submit-tip-or-compl...
0 · Reply
profitingstocks
profitingstocks Feb. 3 at 3:12 PM
$OGEN Oh look, another “strategic partnership” we’ll never hear about again. Just another excuse for a press release to string along the gullible
1 · Reply
NMax
NMax Feb. 3 at 2:57 PM
$OGEN
0 · Reply
DARKP00L
DARKP00L Feb. 3 at 1:39 PM
$OGEN 08:35 on Feb. 03 2026 Oragenics Engages DUCK FLATS Pharma As It U.S. Investigational New Drug Readiness, Regulatory Execution Partner To Support FDA-Facing Preparation, Clinical Study Design #tradeideas
0 · Reply
RocketQueen
RocketQueen Feb. 3 at 1:31 AM
$OGEN bankruptcy more likely than success with the nasal scam.
0 · Reply
RocketQueen
RocketQueen Feb. 2 at 4:26 PM
$OGEN the patents and IP are worth nothing here because they have not staff left or expertise to do anything with the skeletal remains of this company. An honest response from the BOD here would be to take the 15M and put it in reserve to pay off chapter 11 costs and eventual class action lawsuits.
0 · Reply
profitingstocks
profitingstocks Feb. 2 at 3:50 PM
$OGEN Paying to have a booth at a summit to tell people you have no products, just a failed worthless patent. What a great way to spend the money they steal from investors
0 · Reply
Latest News on OGEN
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

Feb 3, 2026, 8:30 AM EST - 17 hours ago

Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

Oragenics Q3 2025 Shareholder Update

Nov 12, 2025, 8:30 AM EST - 2 months ago

Oragenics Q3 2025 Shareholder Update

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Oct 21, 2025, 8:00 AM EDT - 3 months ago

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

Oct 7, 2025, 8:30 AM EDT - 4 months ago

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

Oragenics Q2 2025 Shareholder Update

Aug 11, 2025, 8:45 AM EDT - 6 months ago

Oragenics Q2 2025 Shareholder Update

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Jul 16, 2025, 8:39 AM EDT - 7 months ago

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Oragenics Completes Approximately $16.5 Million Offering

Jul 2, 2025, 4:15 PM EDT - 7 months ago

Oragenics Completes Approximately $16.5 Million Offering

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Jul 1, 2025, 8:31 AM EDT - 7 months ago

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 13, 2025, 8:30 AM EDT - 9 months ago

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

May 12, 2025, 8:30 AM EDT - 9 months ago

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Apr 7, 2025, 4:30 PM EDT - 10 months ago

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Mar 27, 2025, 8:30 AM EDT - 11 months ago

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Mar 18, 2025, 5:33 PM EDT - 11 months ago

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Mar 6, 2025, 9:30 AM EST - 11 months ago

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Feb 25, 2025, 8:30 AM EST - 1 year ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Feb 11, 2025, 8:30 AM EST - 1 year ago

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Feb 5, 2025, 8:15 AM EST - 1 year ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Jan 21, 2025, 8:15 AM EST - 1 year ago

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Dec 16, 2024, 8:09 AM EST - 1 year ago

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oct 18, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oct 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. Announces Closing of Public Offering

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Announces Closing of Public Offering

Oragenics, Inc. Announces Pricing of Public Offering

Sep 4, 2024, 8:36 AM EDT - 1 year ago

Oragenics, Inc. Announces Pricing of Public Offering

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Aug 21, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Aug 16, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Aug 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Oragenics, Inc. Announces Proposed Public Offering

Jun 24, 2024, 6:43 PM EDT - 1 year ago

Oragenics, Inc. Announces Proposed Public Offering

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

May 22, 2024, 8:00 AM EDT - 1 year ago

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

May 17, 2024, 8:00 AM EDT - 1 year ago

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Apr 19, 2024, 5:50 PM EDT - 1 year ago

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Oragenics, Inc. Files 10K and Provides Company Update

Apr 1, 2024, 9:05 AM EDT - 2 years ago

Oragenics, Inc. Files 10K and Provides Company Update

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Mar 5, 2024, 7:45 AM EST - 2 years ago

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Closing of Public Offering

Mar 1, 2024, 4:04 PM EST - 2 years ago

Oragenics Announces Closing of Public Offering

Oragenics Announces Pricing of Public Offering

Feb 27, 2024, 9:25 PM EST - 2 years ago

Oragenics Announces Pricing of Public Offering

Oragenics Announces Proposed Public Offering

Feb 27, 2024, 4:33 PM EST - 2 years ago

Oragenics Announces Proposed Public Offering

Oragenics, Inc. Announces Leadership Transition

Feb 12, 2024, 4:41 PM EST - 2 years ago

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Feb 7, 2024, 8:00 AM EST - 2 years ago

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Feb 5, 2024, 8:00 AM EST - 2 years ago

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Termination of At-The-Market Offering Program

Jan 23, 2024, 5:34 PM EST - 2 years ago

Oragenics Announces Termination of At-The-Market Offering Program

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Jan 2, 2024, 7:30 AM EST - 2 years ago

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Oragenics Issues Update to Shareholders

Nov 2, 2023, 7:00 AM EDT - 2 years ago

Oragenics Issues Update to Shareholders

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oct 18, 2023, 8:30 AM EDT - 2 years ago

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oct 18, 2023, 8:30 AM EDT - 2 years ago

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Oct 5, 2023, 6:30 AM EDT - 2 years ago

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

Sep 29, 2023, 4:00 PM EDT - 2 years ago

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

RocketQueen
RocketQueen Feb. 4 at 12:57 AM
$OGEN headed for non compliance again
0 · Reply
NMax
NMax Feb. 3 at 8:28 PM
$OGEN Janet Huffman and the Oragenics board appear to be coordinating with Sabby for a pump and dump soon
0 · Reply
RocketQueen
RocketQueen Feb. 3 at 7:14 PM
$OGEN Duck Flats Pharma? Looks like more turd polishing.
0 · Reply
NMax
NMax Feb. 3 at 4:53 PM
$OGEN Investigate Janet (and probably Tony Huffman) and the Oragenics board for defrauding investors with fake project developments/timelines, what appears to be collusion with sabby to manipulate share price and especially the board for allowing such rampant fraud and negligence. Janet and Anthony's other businesses (below) should be investigated for connections to Oragenics as well as any trades related to SOGEN: 4KIDZ Consulting LLC Barrel Brands LLC Florida Office of the Attorney General, Dept. of Legal Affairs: (850) 414-3990 Fbl submit a tip: tips.fbi.gov/violation-sele... SEC submit a tip. sec.gov/submit-tip-or-compl...
0 · Reply
profitingstocks
profitingstocks Feb. 3 at 3:12 PM
$OGEN Oh look, another “strategic partnership” we’ll never hear about again. Just another excuse for a press release to string along the gullible
1 · Reply
NMax
NMax Feb. 3 at 2:57 PM
$OGEN
0 · Reply
DARKP00L
DARKP00L Feb. 3 at 1:39 PM
$OGEN 08:35 on Feb. 03 2026 Oragenics Engages DUCK FLATS Pharma As It U.S. Investigational New Drug Readiness, Regulatory Execution Partner To Support FDA-Facing Preparation, Clinical Study Design #tradeideas
0 · Reply
RocketQueen
RocketQueen Feb. 3 at 1:31 AM
$OGEN bankruptcy more likely than success with the nasal scam.
0 · Reply
RocketQueen
RocketQueen Feb. 2 at 4:26 PM
$OGEN the patents and IP are worth nothing here because they have not staff left or expertise to do anything with the skeletal remains of this company. An honest response from the BOD here would be to take the 15M and put it in reserve to pay off chapter 11 costs and eventual class action lawsuits.
0 · Reply
profitingstocks
profitingstocks Feb. 2 at 3:50 PM
$OGEN Paying to have a booth at a summit to tell people you have no products, just a failed worthless patent. What a great way to spend the money they steal from investors
0 · Reply
prinsbernhhard
prinsbernhhard Feb. 2 at 2:28 PM
$OGEN
2 · Reply
RocketQueen
RocketQueen Feb. 1 at 1:19 AM
$OGEN will be under fifty cents soon. The only range to buy OGEN is near thirty cents with risk of another R/S if Janet continues the grift.
0 · Reply
PAInv
PAInv Jan. 31 at 8:51 PM
$OGEN Abbit has blood test for concussions ! Will they buy OGEN?https://abbott.mediaroom.com/2024-04-01-Abbott-Receives-FDA-Clearance-for-Whole-Blood-Rapid-Test-to-Help-with-Assessment-of-Concussion-at-the-Patients-Bedside#:~:text=Abbott's%20i%2DSTAT%20TBI%20cartridge%20is%20a%20whole,(UCH%2DL1)%20*%20Glial%20fibrillary%20acidic%20protein%20(GFAP)
1 · Reply
PAInv
PAInv Jan. 31 at 8:46 PM
$OGEN plus ODYY - going to tge bank this Spring baby!
0 · Reply
Dh15708
Dh15708 Jan. 30 at 9:13 PM
$OGEN pump and dump is coming soon .🤷🤷
1 · Reply
RocketQueen
RocketQueen Jan. 29 at 6:43 PM
$OGEN a miracle this trash is holding .80
0 · Reply
NMax
NMax Jan. 29 at 2:19 PM
$OGEN The CEO of Oragenics, Janet Huffman appears to be an imposter who is fraudulently running Oragenics as a (now) shell company. She also appears to be colluding with Hedge-funds such as sabby to manipulate share price Janet and Tony Huffman appear to have run other possible shell companies such as 4KIDZ CONSULTING, LLC BARREL BRANDS, LLC. Tony Huffmans involvement with Oragenics needs to be investigated. As does the activity of the Oragenics Board of Directors who have overseen this dumpster fire of a company.
1 · Reply
RocketQueen
RocketQueen Jan. 29 at 12:01 AM
$OGEN sold this garbage last april and put the remainder into another stock that has been up over 300%. Meanwhile, OGEN dropped by over 90% since I sold. Janet should be arrested and jailed for making zero progress after R/S and more dilution incoming.
0 · Reply
NMax
NMax Jan. 28 at 5:27 PM
$OGEN I'll be requesting federal authorities look at connections between Janet and Tony Huffmans other businesses and Oragenics. 4KIDZ CONSULTING, LLC BARREL BRANDS, LLC I will only get LOUDER and draw as much attention to the fraud happening here between Oragenics and potentially sabby to manipulate share price
1 · Reply
NMax
NMax Jan. 28 at 3:40 PM
$OGEN the boogymans coming for these frauds And I'm only going to get louder.
1 · Reply
NMax
NMax Jan. 28 at 1:22 PM
$OGEN Janet Huffman and those associated with her will need to be investigated. This fraud has gone on long enough. https://tips.fbi.gov/violation-selection
0 · Reply
NMax
NMax Jan. 27 at 9:51 PM
$OGEN How does Janet have time to be CFO/CEO/President/Treasurer here when she and Tony Huffman also have/had at least two other businesses together? 4KIDZ CONSULTING, LLC (up until 2024?) Barrel Brands, LLC (still active...in fact it was created just as 4Kidz was closing in 2024 🤔...a bit suspicious) Are these shell companies too?
1 · Reply